<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Interleukin 23 (IL-23) affects <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> by regulating Th cells and plays a vital role in immunosuppression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="1" pm="."><plain>However, whether <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells are IL-23R positive or whether IL-23 has the potential to influence the growth of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells directly remains unclear </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to clarify the molecular expression patterns of IL-23, IL-23R, and Forkhead box P3 (FOXP3) in <z:mpath ids='MPATH_458'>normal</z:mpath> tissues adjacent to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, in <z:hpo ids='HP_0005266'>intestinal polyps</z:hpo> (IP), and in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and to infer the relationship between the expression patterns of these three molecules and the progress of <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumors</z:e> from <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The levels of IL-23A, IL-23R, and FOXP3 were evaluated in <z:mpath ids='MPATH_458'>normal</z:mpath> tissues adjacent to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (NT, n = 13), IP (n = 26), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (n = 13) using real-time PCR, ELISA, western blotting, immunohistochemistry, and immunocytochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The expression of IL-23 and FOXP3 increased progressively from NT through to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Immunohistochemistry staining showed that IL-23R was highly positive in <z:mp ids='MP_0002038'>carcinoma</z:mp> cells of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> group, whereas it was partially positive in cells of other groups </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, the human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line SW-480 exhibited weak IL-23R immunocytochemical positivity </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: We propose that the IL-23/IL-23R pathway is a potential route to facilitate the malignant progression of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The relationship between IL-23 and FOXP3 in the microenvironment of <z:mp ids='MP_0002038'>carcinoma</z:mp> led us to deduce that these two molecules may interact with each other </plain></SENT>
<SENT sid="9" pm="."><plain>Although the exact mechanism underlying this interaction remains a mystery, we are convinced that these two molecules are relevant in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> and that IL-23 could be a potential target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy </plain></SENT>
</text></document>